Key takeaway: Dr. Reddy's Laboratories Limited reported a revenue decline of 5.6% for Q1 FY27, with consolidated revenues at ₹8,071 crores (US$853 million). The decline was attributed to lower lenalidomide revenues and a provision of ₹240 crores related to semaglutide API challenges. However, the underlying base business showed healthy double-digit growth across key geographies, including North America. The EBITDA margin was reported at 12.5%, impacted by the semaglutide-related issues and higher costs due to the Middle East conflict. Management highlighted strong performance in the India and Emerging Markets segments, with India achieving 17% year-on-year growth. The company plans to resume semaglutide supplies by November and remains focused on strategic priorities in peptides, biosimilars, and consumer health. The earnings call included discussions on regulatory updates, product launches, and ongoing productivity initiatives.

Key takeaway: On July 22, 2026, Dr. Reddy's Laboratories Limited provided an update on its Q1 FY27 unaudited financial results. The presentation reported a revenue of ₹8,071 crore, reflecting a 6% year-over-year increase and a 7% quarter-over-quarter increase. EBITDA was reported at ₹1,009 crore, with a margin of 12.5%, while profit before tax (PBT) reached ₹553 crore, marking a 71% year-over-year increase. The company highlighted significant business developments, including the first-to-market launch of bosutinib in the US and the launch of generic semaglutide in Canada. The presentation also noted challenges, such as the impact of semaglutide API-related costs and increased operational expenses due to geopolitical factors. Additionally, Dr. Reddy's celebrated its 25th anniversary of listing on the NYSE and received recognition for sustainability efforts. The document emphasized ongoing strategic priorities and growth initiatives across various segments.

Key takeaway: Dr. Reddy's Laboratories Ltd. provided a transcript of its earnings call conducted on May 12, 2026, discussing the financial results for the quarter and financial year ended March 31, 2026. The document included details about the company's performance and was made available on their website. The communication was addressed to the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd., indicating compliance with regulatory requirements.

Key takeaway: On May 12, 2026, Dr. Reddy's Laboratories Limited provided an investor presentation detailing its audited financial results for Q4 and FY26. The presentation reported a 12% year-over-year increase in revenues for Q4, totaling ₹7,516 crore, with a 19.5% EBITDA margin before specific items. For FY26, the company reported revenues of ₹33,593 crore, reflecting a 3% year-over-year growth. Management highlighted double-digit growth in the base business and significant achievements, including the launch of a generic semaglutide injection in Canada and the integration of the NRT business. The presentation also noted recognition for sustainability efforts, including a Gold Medal from EcoVadis. However, it acknowledged challenges such as lower sales of lenalidomide and specific one-time adjustments impacting financial results.